Insulet Reports Third Quarter 2026 Financial Results and Announces $1 Billion Share Repurchase Program

Insulet reported third-quarter 2026 revenue of $842.0 million, up 19.2% year over year and above analyst estimates, while adjusted EPS of $1.99 exceeded the $1.59 consensus. Its board approved a $1 billion share repurchase program, with about $400 million expected in the fourth quarter. Insulet raised its fiscal 2026 revenue growth outlook to 21%–22% and said enrollment is complete for its STRIVE2 and EVOLVE clinical trials.